leadf
logo-loader
viewCreso Pharma Ltd

Creso Pharma's second NSLC retail purchase order highlights strong Canadian demand

Mernova’s Ritual Green products are being sold to consumers through NSLC, which is operated by the Nova Scotia provincial government and is the sole distributor of retail recreational cannabis in the region.

Creso Pharma Ltd - Creso Pharma subsidiary Mernova receives second Retail PO from Nova Scotia Liquor Corporation
The Ritual Green Mimosa strain (15-20% THC and < 1% CBD) is ready for recreational market launch

Creso Pharma Ltd’s (ASX:CPH) (FRA:1X8) wholly-owned Canadian subsidiary Mernova Medicinal Inc has received and delivered a second purchase order valued at C$138,960 from the Nova Scotia Liquor Corporation (NSLC).

The NSLC is operated by the Nova Scotia provincial government and is the sole distributor of retail recreational cannabis in Nova Scotia with the new order highlighting strong product demand in the Canadian recreational market.

It follows an initial order from the NSLC valued at C$180,00 for two of Mernova’s premium strains, HPG13 at 20-25% THC and <1% CBD, and Lemon Haze at 20-25% THC and <1% CBD, sold under the Ritual Green brand.

“Recurring purchase orders”

Mernova managing director Jack Yu said: “The second purchase order in as many weeks from the NSLC reinforces the significant demand that we are witnessing for our retail product offerings, and further highlights Creso Pharma and Mernova’s potential as a supplier to a rapidly growing recreational market.

“Our products are seen as very high quality, and we are confident that the launch of initial strains under the Ritual Green brand will help position Mernova as a leader in the production of locally grown, artisanal cannabis products, and lead to recurring purchase orders from the NSLC.”

The Ritual Green recreational products now being sold through the NSLC’s stores and e-commerce platform with initial products being well received and generating strong sales.

“Launching new strains”

Mernova is ramping up production to meet increasing demands with additional POs expected in the near term.

Yu said: “We will continue to ramp-up production, and adjust our planning and grow scheduling, which will allow us to meet the supply chain demands of the NSLC and other provincial purchasers.

“Additional purchase orders and the launch of new strains are anticipated in the near term, and I look forward to updating shareholders upon these launches and additional sales.”

Quick facts: Creso Pharma Ltd

Price: 0.1 AUD

ASX:CPH
Market: ASX
Market Cap: $68.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 11/6/20

2 min read